This page uses content from Wikipedia and is licensed under CC BY-SA.


Ro60-0213 structure.png
PubChem CID
Chemical and physical data
Molar mass244.331 g/mol g·mol−1
3D model (JSmol)

Ro60-0213 (Org 35032) is a drug developed by Hoffmann–La Roche, which acts as a potent and selective agonist for the 5-HT2C serotonin receptor, with more than 100x selectivity over other closely related serotonin receptor subtypes, and little or no affinity at other receptors. It was developed as a potential antidepressant,[1] but was discontinued from clinical development at an early stage due to toxicity concerns.[2] However the high selectivity of Ro60-0213 for 5-HT2C makes it of continued interest for research into serotonin receptors.[3]

See also


  1. ^ Leysen D, Kelder J (1998). "Ligands for the 5-HT2C receptor as potential antidepressants and anxiolytics". Trends in Drug Research II, Proceedings of the 11th Noordwijkerhout-Camerino Symposium. Pharmacochemistry Library. 29. pp. 49–61. doi:10.1016/S0165-7208(98)80044-5. ISBN 9780444826336.
  2. ^ Albertini S, Bös M, Gocke E, Kirchner S, Muster W, Wichmann J (July 1998). "Suppression of mutagenic activity of a series of 5HT2c receptor agonists by the incorporation of a gem-dimethyl group: SAR using the Ames test and a DNA unwinding assay". Mutagenesis. 13 (4): 397–403. doi:10.1093/mutage/13.4.397. PMID 9717178.
  3. ^ Shimada I, Maeno K, Kazuta K, Kubota H, Kimizuka T, Kimura Y, et al. (February 2008). "Synthesis and structure-activity relationships of a series of substituted 2-(1H-furo[2,3-g]indazol-1-yl)ethylamine derivatives as 5-HT2C receptor agonists". Bioorganic & Medicinal Chemistry. 16 (4): 1966–82. doi:10.1016/j.bmc.2007.10.100. PMID 18035544.